Free Trial
NASDAQ:SLN

Silence Therapeutics Q2 2023 Earnings Report

Silence Therapeutics logo
$3.93 -0.08 (-2.00%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$4.04 +0.12 (+2.93%)
As of 05/2/2025 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Silence Therapeutics EPS Results

Actual EPS
-$0.36
Consensus EPS
-$0.59
Beat/Miss
Beat by +$0.23
One Year Ago EPS
N/A

Silence Therapeutics Revenue Results

Actual Revenue
$11.40 million
Expected Revenue
$1.94 million
Beat/Miss
Beat by +$9.46 million
YoY Revenue Growth
N/A

Silence Therapeutics Announcement Details

Quarter
Q2 2023
Time
N/A
Conference Call Date
Wednesday, August 16, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

Silence Therapeutics' Q1 2025 earnings is scheduled for Thursday, May 15, 2025, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Silence Therapeutics Earnings Headlines

Trump’s Bitcoin Reserve is No Accident…
Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new blockchain development…
See More Silence Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Silence Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Silence Therapeutics and other key companies, straight to your email.

About Silence Therapeutics

Silence Therapeutics (NASDAQ:SLN), a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

View Silence Therapeutics Profile

More Earnings Resources from MarketBeat